Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 17;2(1):63.
doi: 10.1186/s44263-024-00095-w.

Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface

Affiliations

Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface

Jacques Eugene Raubenheimer et al. BMC Glob Public Health. .

Abstract

Background: Off-label use of semaglutide for non-diabetic weight loss (which regulators have linked to social media promotion) created worldwide supply shortages. We evaluated worldwide semaglutide interest measured by online search behavior to gauge social media and conventional print media reporting's effect on search interest.

Methods: Using Google Trends Extended for Health (GTEH) multiple sampling, we retrieved regional online interest (ROI) for all countries and extracted timelines and top search queries for January 2021-August 2023 for countries with median ROI ≥ 20 using the "semaglutide" topic. We obtained semaglutide media reporting from the ProQuest database. We estimated the effect of media and within-country semaglutide interest on between-country interest with Granger causality analysis. We determined changepoints for trends within each country with joinpoint regression. We determined prominent themes in search queries for each country with natural language processing thematic analysis.

Results: Twenty-seven countries were included. Most countries showed an increase in semaglutide interest over time, with Canada and the USA showing the largest sustained interest. Most of the search interest arose from 2022 onwards. Granger's analysis showed that media coverage could only partially explain interest, and interest in some countries partially preceded interest in others, with the UK and Germany showing strong relationships between news reports and lagged search interest. Joinpoint analysis identified up to four significant within-country changepoints. Most countries showed significant positive weekly trends in 2021-2022, although uptrends in search interest varied considerably between countries. One episode of the Dr. Oz show (TV media event) coincided with strong peaks in numerous countries. Natural language processing of top search queries showed some agreement between countries and country-specific themes. Weight loss was a major theme in most countries, while a diabetes theme was generally absent or weak. Some countries (Australia, Chile, South Africa, UK) had themes for buying Ozempic from (named) local retailers, and Germany had a theme related to buying Ozempic without a script.

Conclusions: GTEH data provided insights into global search interest in semaglutide and regional variation. Studies focusing on specific countries which include social media data can elucidate specific drivers behind the surge in off-label use of semaglutide.

Keywords: Diversion; GLP-1 receptor agonist; Google Trends Extended for Health; Infodemiology; Information seeking behavior; Semaglutide; Weight loss.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate.: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Regional online interest worldwide (a) and with an enlargement of Europe (b)
Fig. 2
Fig. 2
Per-country semaglutide Google searches from January 2019 to August 2023. Semaglutide (topic) online search probability (× 10 million); ROI: regional online interest values (Scale 0–100)
Fig. 3
Fig. 3
Granger causality significance test for news about semaglutide and its impact on Google searches, 2019–2023
Fig. 4
Fig. 4
Granger causality significance tests (p < 0.01) for ProQuest as a sole and combined predictor of search probability trends in all countries. Red lines indicate significant paths for ProQuest. Black lines indicate significant paths between countries. Continents coded as follows: Africa (purple), Australiasia (orange), Europe (green), Middle East (blue), North America (red), South America (yellow)
Fig. 5
Fig. 5
Google Trends Extended for Health Raw search probabilities for twenty five countries plotted against social media events

References

    1. World Health Organization (WHO). The top 10 causes of death. Fact Sheets. 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
    1. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–51. - DOI - PMC - PubMed
    1. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10(APR):155. - DOI - PMC - PubMed
    1. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–80. - DOI - PubMed
    1. Kalra S, Gupta Y. Once-weekly glucagon-like peptide 1 receptor agonists. J Pak Med Assoc. 2015;65(7):796–8. - PubMed

LinkOut - more resources